Relapsing remitting multiple sclerosis Trials in Moscow, Russia
Conditions / Relapsing remitting multiple sclerosis / Moscow, Russia
Relapsing remitting multiple sclerosis has been the subject of sustained clinical investigation across multiple research sites.
27 total trials for this combination
Showing top 10 of 27 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01578785 | An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | PHASE3 |
| NCT01963611 | Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) | TERMINATED | PHASE2 |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT00879658 | Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis | COMPLETED | PHASE2 |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | TERMINATED | PHASE3 |
| NCT02255656 | Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 | COMPLETED | PHASE4 |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo | COMPLETED | PHASE3 |
| NCT00882999 | A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE2 |
| NCT00641537 | CLARITY Extension Study | COMPLETED | PHASE3 |
| NCT00078338 | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis | COMPLETED | PHASE4 |